Indian pharma market expands 10.7% in August despite volume headwinds

India's pharmaceutical market maintained its growth momentum in August despite facing volume constraints, with retail sales value expanding 10.7% to reach Rs 23,272 crore, according to latest market data. The sector's value-led expansion comes even as volume growth hit a three-month low, highlighting a shift toward premium formulations and newly introduced medications.

New introductions and launches constituted a significant driver of market expansion during the period. Key therapeutic segments registered double-digit growth, with acute care treatments and chronic disease therapies both contributing meaningfully to the overall increase. This performance underscores the market's continued appetite for innovative treatments and newer pharmaceutical offerings.

The divergence between value and volume growth reflects broader trends in India's healthcare landscape, where prescribers increasingly favour newer formulations and branded generics despite pricing pressures. While volume metrics suggest cautious purchasing patterns—potentially influenced by seasonal factors or inventory adjustments—the value-based expansion indicates that pharmaceutical companies have successfully driven uptake of higher-margin products.

The August figures suggest the Indian pharma sector remains on a growth trajectory, though market participants will likely monitor whether volume constraints persist in coming months. The reliance on new product introductions to sustain value growth underscores the sector's need for continued innovation to maintain competitiveness and address evolving therapeutic needs.